Zolantidine
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H27N3OS |
Molar mass | 381.54 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Zolantidine is a brain-penetrating selective histamine H2 receptor (HRH2) antagonist developed by Smith, Kline & French, with the research code of SK&F 95282. It is a benzthiazole derivative with a 30-fold higher potency for H2 receptors than other peripheral and central receptors.[1]
References
- ↑ Calcutt CR, Ganellin CR, Griffiths R, Leigh BK, Maguire JP, Mitchell RC, et al. (January 1988). "Zolantidine (SK&F 95282) is a potent selective brain-penetrating histamine H2-receptor antagonist". British Journal of Pharmacology. 93 (1): 69–78. doi:10.1111/j.1476-5381.1988.tb11406.x. PMC 1853786. PMID 2894879.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.